Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
Identifieur interne : 000274 ( Main/Exploration ); précédent : 000273; suivant : 000275Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
Auteurs : Danuta M. Skowronski ; Naveed Z. Janjua ; Suzana Sabaiduc ; Gaston De Serres ; Anne-Luise Winter ; Jonathan B. Gubbay ; James A. Dickinson ; Kevin Fonseca ; Hugues Charest ; Nathalie Bastien ; Yan Li ; Trijntje L. Kwindt ; Salaheddin M. Mahmud ; Paul Van Caeseele ; Mel Krajden ; Martin PetricSource :
- The Journal of infectious diseases [ 1537-6613 ] ; 2014.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Analyse de séquence d'ADN, Antigènes viraux (génétique), Antigènes viraux (immunologie), Canada (épidémiologie), Données de séquences moléculaires, Enfant, Enfant d'âge préscolaire, Femelle, Glycoprotéine hémagglutinine du virus influenza (génétique), Glycoprotéine hémagglutinine du virus influenza (immunologie), Grippe humaine (), Grippe humaine (immunologie), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains, Jeune adulte, Mâle, Nourrisson, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Tests d'inhibition de l'hémagglutination, Vaccination (), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Virus de la grippe A (), Virus de la grippe A (génétique), Virus de la grippe A (immunologie), Virus de la grippe A (isolement et purification), Virus influenza B (), Virus influenza B (génétique), Virus influenza B (immunologie), Virus influenza B (isolement et purification), Études cas-témoins.
- MESH :
- administration et posologie : Vaccins antigrippaux.
- génétique : Antigènes viraux, Glycoprotéine hémagglutinine du virus influenza, Virus de la grippe A, Virus influenza B.
- immunologie : Antigènes viraux, Glycoprotéine hémagglutinine du virus influenza, Grippe humaine, Vaccins antigrippaux, Virus de la grippe A, Virus influenza B.
- isolement et purification : Virus de la grippe A, Virus influenza B.
- virologie : Grippe humaine.
- épidémiologie : Canada, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Analyse de séquence d'ADN, Données de séquences moléculaires, Enfant, Enfant d'âge préscolaire, Femelle, Grippe humaine, Humains, Jeune adulte, Mâle, Nourrisson, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Tests d'inhibition de l'hémagglutination, Vaccination, Virus de la grippe A, Virus influenza B, Études cas-témoins.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Antigens, Viral (genetics), Antigens, Viral (immunology), Canada (epidemiology), Case-Control Studies, Child, Child, Preschool, Female, Hemagglutination Inhibition Tests, Hemagglutinin Glycoproteins, Influenza Virus (genetics), Hemagglutinin Glycoproteins, Influenza Virus (immunology), Humans, Infant, Influenza A virus (classification), Influenza A virus (genetics), Influenza A virus (immunology), Influenza A virus (isolation & purification), Influenza B virus (classification), Influenza B virus (genetics), Influenza B virus (immunology), Influenza B virus (isolation & purification), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Male, Middle Aged, Molecular Sequence Data, Sequence Analysis, DNA, Treatment Outcome, Vaccination (methods), Young Adult.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , genetics : Antigens, Viral, Hemagglutinin Glycoproteins, Influenza Virus.
- chemical , immunology : Antigens, Viral, Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines.
- geographic , epidemiology : Canada.
- classification : Influenza A virus, Influenza B virus.
- epidemiology : Influenza, Human.
- genetics : Influenza A virus, Influenza B virus.
- immunology : Influenza A virus, Influenza B virus, Influenza, Human.
- isolation & purification : Influenza A virus, Influenza B virus.
- methods : Vaccination.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Adult, Aged, Aged, 80 and over, Case-Control Studies, Child, Child, Preschool, Female, Hemagglutination Inhibition Tests, Humans, Infant, Male, Middle Aged, Molecular Sequence Data, Sequence Analysis, DNA, Treatment Outcome, Young Adult.
Abstract
BACKGROUND
We estimate vaccine effectiveness (VE) against both influenza A/subtypes and B/lineages in Canada for the 2011-2012 trivalent inactivated influenza vaccine (TIV) with components entirely unchanged from the 2010-2011 TIV and in the context of phenotypic and genotypic characterization of circulating viruses.
METHODS
In a test-negative case-control study VE was estimated as [1-(adjusted)OddsRatio] × 100 for RT-PCR-confirmed influenza in vaccinated vs nonvaccinated participants. Viruses were characterized by hemagglutination inhibition (HI) and sequencing of antigenic sites of the hemagglutinin (HA) gene.
RESULTS
There were 1507 participants. VE against A(H1N1)pdm09 was 80% (95% confidence interval [CI], 52%-92%): circulating viruses were HI-characterized as vaccine-matched and bore just 2 aminoacid (AA) differences from vaccine. VE against A/H3N2 was 51% (95% CI, 10%-73%): circulating viruses were HI-characterized as vaccine-related but bore ≥11AA differences from vaccine. VE against influenza B was 51% (95% CI, 26%-67%) in total: 71% (95% CI, 40%-86%) for lineage-matched B/Victoria and 27% (95% CI, -21% to 56%) for lineage-mismatched B/Yamagata. For both influenza A and B types, VE was similar among recipients of either 2010-2011 or 2011-2012 TIV alone, higher when vaccinated both seasons.
CONCLUSIONS
Phenotypic and genotypic characterization of circulating and vaccine viruses enhances understanding of TIV performance, shown in 2011-2012 to be substantial against well-conserved A(H1N1)pdm09 and lineage-matched influenza B, suboptimal against genetic-variants of A/H3N2, and further reduced against lineage-mismatched influenza B. With unchanged vaccine components, protection may extend beyond a single season.
DOI: 10.1093/infdis/jiu048
PubMed: 24446529
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.</title><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name></author><author><name sortKey="Janjua, Naveed Z" sort="Janjua, Naveed Z" uniqKey="Janjua N" first="Naveed Z" last="Janjua">Naveed Z. Janjua</name></author><author><name sortKey="Sabaiduc, Suzana" sort="Sabaiduc, Suzana" uniqKey="Sabaiduc S" first="Suzana" last="Sabaiduc">Suzana Sabaiduc</name></author><author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name></author><author><name sortKey="Winter, Anne Luise" sort="Winter, Anne Luise" uniqKey="Winter A" first="Anne-Luise" last="Winter">Anne-Luise Winter</name></author><author><name sortKey="Gubbay, Jonathan B" sort="Gubbay, Jonathan B" uniqKey="Gubbay J" first="Jonathan B" last="Gubbay">Jonathan B. Gubbay</name></author><author><name sortKey="Dickinson, James A" sort="Dickinson, James A" uniqKey="Dickinson J" first="James A" last="Dickinson">James A. Dickinson</name></author><author><name sortKey="Fonseca, Kevin" sort="Fonseca, Kevin" uniqKey="Fonseca K" first="Kevin" last="Fonseca">Kevin Fonseca</name></author><author><name sortKey="Charest, Hugues" sort="Charest, Hugues" uniqKey="Charest H" first="Hugues" last="Charest">Hugues Charest</name></author><author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name></author><author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name></author><author><name sortKey="Kwindt, Trijntje L" sort="Kwindt, Trijntje L" uniqKey="Kwindt T" first="Trijntje L" last="Kwindt">Trijntje L. Kwindt</name></author><author><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name></author><author><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name></author><author><name sortKey="Krajden, Mel" sort="Krajden, Mel" uniqKey="Krajden M" first="Mel" last="Krajden">Mel Krajden</name></author><author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24446529</idno><idno type="pmid">24446529</idno><idno type="doi">10.1093/infdis/jiu048</idno><idno type="wicri:Area/Main/Corpus">000297</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000297</idno><idno type="wicri:Area/Main/Curation">000297</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000297</idno><idno type="wicri:Area/Main/Exploration">000297</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.</title><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name></author><author><name sortKey="Janjua, Naveed Z" sort="Janjua, Naveed Z" uniqKey="Janjua N" first="Naveed Z" last="Janjua">Naveed Z. Janjua</name></author><author><name sortKey="Sabaiduc, Suzana" sort="Sabaiduc, Suzana" uniqKey="Sabaiduc S" first="Suzana" last="Sabaiduc">Suzana Sabaiduc</name></author><author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name></author><author><name sortKey="Winter, Anne Luise" sort="Winter, Anne Luise" uniqKey="Winter A" first="Anne-Luise" last="Winter">Anne-Luise Winter</name></author><author><name sortKey="Gubbay, Jonathan B" sort="Gubbay, Jonathan B" uniqKey="Gubbay J" first="Jonathan B" last="Gubbay">Jonathan B. Gubbay</name></author><author><name sortKey="Dickinson, James A" sort="Dickinson, James A" uniqKey="Dickinson J" first="James A" last="Dickinson">James A. Dickinson</name></author><author><name sortKey="Fonseca, Kevin" sort="Fonseca, Kevin" uniqKey="Fonseca K" first="Kevin" last="Fonseca">Kevin Fonseca</name></author><author><name sortKey="Charest, Hugues" sort="Charest, Hugues" uniqKey="Charest H" first="Hugues" last="Charest">Hugues Charest</name></author><author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name></author><author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name></author><author><name sortKey="Kwindt, Trijntje L" sort="Kwindt, Trijntje L" uniqKey="Kwindt T" first="Trijntje L" last="Kwindt">Trijntje L. Kwindt</name></author><author><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name></author><author><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name></author><author><name sortKey="Krajden, Mel" sort="Krajden, Mel" uniqKey="Krajden M" first="Mel" last="Krajden">Mel Krajden</name></author><author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name></author></analytic><series><title level="j">The Journal of infectious diseases</title><idno type="eISSN">1537-6613</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antigens, Viral (genetics)</term><term>Antigens, Viral (immunology)</term><term>Canada (epidemiology)</term><term>Case-Control Studies</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Hemagglutinin Glycoproteins, Influenza Virus (genetics)</term><term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term><term>Humans</term><term>Infant</term><term>Influenza A virus (classification)</term><term>Influenza A virus (genetics)</term><term>Influenza A virus (immunology)</term><term>Influenza A virus (isolation & purification)</term><term>Influenza B virus (classification)</term><term>Influenza B virus (genetics)</term><term>Influenza B virus (immunology)</term><term>Influenza B virus (isolation & purification)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Male</term><term>Middle Aged</term><term>Molecular Sequence Data</term><term>Sequence Analysis, DNA</term><term>Treatment Outcome</term><term>Vaccination (methods)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de séquence d'ADN</term><term>Antigènes viraux (génétique)</term><term>Antigènes viraux (immunologie)</term><term>Canada (épidémiologie)</term><term>Données de séquences moléculaires</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Glycoprotéine hémagglutinine du virus influenza (génétique)</term><term>Glycoprotéine hémagglutinine du virus influenza (immunologie)</term><term>Grippe humaine ()</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (virologie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccination ()</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Virus de la grippe A ()</term><term>Virus de la grippe A (génétique)</term><term>Virus de la grippe A (immunologie)</term><term>Virus de la grippe A (isolement et purification)</term><term>Virus influenza B ()</term><term>Virus influenza B (génétique)</term><term>Virus influenza B (immunologie)</term><term>Virus influenza B (isolement et purification)</term><term>Études cas-témoins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, Viral</term><term>Hemagglutinin Glycoproteins, Influenza Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term><term>Hemagglutinin Glycoproteins, Influenza Virus</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigènes viraux</term><term>Glycoprotéine hémagglutinine du virus influenza</term><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes viraux</term><term>Glycoprotéine hémagglutinine du virus influenza</term><term>Grippe humaine</term><term>Vaccins antigrippaux</term><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A virus</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Virus de la grippe A</term><term>Virus influenza B</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Molecular Sequence Data</term><term>Sequence Analysis, DNA</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse de séquence d'ADN</term><term>Données de séquences moléculaires</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tests d'inhibition de l'hémagglutination</term><term>Vaccination</term><term>Virus de la grippe A</term><term>Virus influenza B</term><term>Études cas-témoins</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>We estimate vaccine effectiveness (VE) against both influenza A/subtypes and B/lineages in Canada for the 2011-2012 trivalent inactivated influenza vaccine (TIV) with components entirely unchanged from the 2010-2011 TIV and in the context of phenotypic and genotypic characterization of circulating viruses.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>In a test-negative case-control study VE was estimated as [1-(adjusted)OddsRatio] × 100 for RT-PCR-confirmed influenza in vaccinated vs nonvaccinated participants. Viruses were characterized by hemagglutination inhibition (HI) and sequencing of antigenic sites of the hemagglutinin (HA) gene.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>There were 1507 participants. VE against A(H1N1)pdm09 was 80% (95% confidence interval [CI], 52%-92%): circulating viruses were HI-characterized as vaccine-matched and bore just 2 aminoacid (AA) differences from vaccine. VE against A/H3N2 was 51% (95% CI, 10%-73%): circulating viruses were HI-characterized as vaccine-related but bore ≥11AA differences from vaccine. VE against influenza B was 51% (95% CI, 26%-67%) in total: 71% (95% CI, 40%-86%) for lineage-matched B/Victoria and 27% (95% CI, -21% to 56%) for lineage-mismatched B/Yamagata. For both influenza A and B types, VE was similar among recipients of either 2010-2011 or 2011-2012 TIV alone, higher when vaccinated both seasons.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Phenotypic and genotypic characterization of circulating and vaccine viruses enhances understanding of TIV performance, shown in 2011-2012 to be substantial against well-conserved A(H1N1)pdm09 and lineage-matched influenza B, suboptimal against genetic-variants of A/H3N2, and further reduced against lineage-mismatched influenza B. With unchanged vaccine components, protection may extend beyond a single season.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24446529</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2014</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>210</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.</ArticleTitle><Pagination><MedlinePgn>126-37</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We estimate vaccine effectiveness (VE) against both influenza A/subtypes and B/lineages in Canada for the 2011-2012 trivalent inactivated influenza vaccine (TIV) with components entirely unchanged from the 2010-2011 TIV and in the context of phenotypic and genotypic characterization of circulating viruses.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a test-negative case-control study VE was estimated as [1-(adjusted)OddsRatio] × 100 for RT-PCR-confirmed influenza in vaccinated vs nonvaccinated participants. Viruses were characterized by hemagglutination inhibition (HI) and sequencing of antigenic sites of the hemagglutinin (HA) gene.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 1507 participants. VE against A(H1N1)pdm09 was 80% (95% confidence interval [CI], 52%-92%): circulating viruses were HI-characterized as vaccine-matched and bore just 2 aminoacid (AA) differences from vaccine. VE against A/H3N2 was 51% (95% CI, 10%-73%): circulating viruses were HI-characterized as vaccine-related but bore ≥11AA differences from vaccine. VE against influenza B was 51% (95% CI, 26%-67%) in total: 71% (95% CI, 40%-86%) for lineage-matched B/Victoria and 27% (95% CI, -21% to 56%) for lineage-mismatched B/Yamagata. For both influenza A and B types, VE was similar among recipients of either 2010-2011 or 2011-2012 TIV alone, higher when vaccinated both seasons.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Phenotypic and genotypic characterization of circulating and vaccine viruses enhances understanding of TIV performance, shown in 2011-2012 to be substantial against well-conserved A(H1N1)pdm09 and lineage-matched influenza B, suboptimal against genetic-variants of A/H3N2, and further reduced against lineage-mismatched influenza B. With unchanged vaccine components, protection may extend beyond a single season.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skowronski</LastName><ForeName>Danuta M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Janjua</LastName><ForeName>Naveed Z</ForeName><Initials>NZ</Initials></Author><Author ValidYN="Y"><LastName>Sabaiduc</LastName><ForeName>Suzana</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>De Serres</LastName><ForeName>Gaston</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Winter</LastName><ForeName>Anne-Luise</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Gubbay</LastName><ForeName>Jonathan B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Dickinson</LastName><ForeName>James A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Fonseca</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Charest</LastName><ForeName>Hugues</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Bastien</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kwindt</LastName><ForeName>Trijntje L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Mahmud</LastName><ForeName>Salaheddin M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Van Caeseele</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Krajden</LastName><ForeName>Mel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Petric</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>KF551067</AccessionNumber><AccessionNumber>KF551068</AccessionNumber><AccessionNumber>KF551069</AccessionNumber><AccessionNumber>KF551070</AccessionNumber><AccessionNumber>KF551071</AccessionNumber><AccessionNumber>KF551072</AccessionNumber><AccessionNumber>KF551073</AccessionNumber><AccessionNumber>KF551074</AccessionNumber><AccessionNumber>KF551075</AccessionNumber><AccessionNumber>KF551076</AccessionNumber><AccessionNumber>KF551077</AccessionNumber><AccessionNumber>KF551078</AccessionNumber><AccessionNumber>KF551079</AccessionNumber><AccessionNumber>KF551080</AccessionNumber><AccessionNumber>KF551081</AccessionNumber><AccessionNumber>KF551082</AccessionNumber><AccessionNumber>KF551083</AccessionNumber><AccessionNumber>KF551084</AccessionNumber><AccessionNumber>KF551085</AccessionNumber><AccessionNumber>KF551086</AccessionNumber><AccessionNumber>KF551087</AccessionNumber><AccessionNumber>KF551088</AccessionNumber><AccessionNumber>KF551089</AccessionNumber><AccessionNumber>KF551090</AccessionNumber><AccessionNumber>KF551091</AccessionNumber><AccessionNumber>KF551092</AccessionNumber><AccessionNumber>KF551093</AccessionNumber><AccessionNumber>KF551094</AccessionNumber><AccessionNumber>KF551095</AccessionNumber><AccessionNumber>KF551096</AccessionNumber><AccessionNumber>KF586723</AccessionNumber><AccessionNumber>KF586724</AccessionNumber><AccessionNumber>KF586725</AccessionNumber><AccessionNumber>KF586726</AccessionNumber><AccessionNumber>KF586727</AccessionNumber><AccessionNumber>KF586728</AccessionNumber><AccessionNumber>KF586729</AccessionNumber><AccessionNumber>KF586730</AccessionNumber><AccessionNumber>KF586731</AccessionNumber><AccessionNumber>KF586732</AccessionNumber><AccessionNumber>KF586733</AccessionNumber><AccessionNumber>KF586734</AccessionNumber><AccessionNumber>KF586735</AccessionNumber><AccessionNumber>KF586736</AccessionNumber><AccessionNumber>KF586737</AccessionNumber><AccessionNumber>KF586738</AccessionNumber><AccessionNumber>KF586739</AccessionNumber><AccessionNumber>KF586740</AccessionNumber><AccessionNumber>KF586741</AccessionNumber><AccessionNumber>KF586742</AccessionNumber><AccessionNumber>KF586743</AccessionNumber><AccessionNumber>KF586744</AccessionNumber><AccessionNumber>KF586745</AccessionNumber><AccessionNumber>KF586746</AccessionNumber><AccessionNumber>KF586747</AccessionNumber><AccessionNumber>KF586748</AccessionNumber><AccessionNumber>KF586749</AccessionNumber><AccessionNumber>KF586750</AccessionNumber><AccessionNumber>KF586751</AccessionNumber><AccessionNumber>KF586752</AccessionNumber><AccessionNumber>KF586753</AccessionNumber><AccessionNumber>KF586754</AccessionNumber><AccessionNumber>KF586755</AccessionNumber><AccessionNumber>KF586756</AccessionNumber><AccessionNumber>KF586757</AccessionNumber><AccessionNumber>KF586758</AccessionNumber><AccessionNumber>KF586759</AccessionNumber><AccessionNumber>KF586760</AccessionNumber><AccessionNumber>KF586761</AccessionNumber><AccessionNumber>KF586762</AccessionNumber><AccessionNumber>KF586763</AccessionNumber><AccessionNumber>KF586764</AccessionNumber><AccessionNumber>KF586765</AccessionNumber><AccessionNumber>KF586766</AccessionNumber><AccessionNumber>KF586767</AccessionNumber><AccessionNumber>KF586768</AccessionNumber><AccessionNumber>KF598702</AccessionNumber><AccessionNumber>KF598703</AccessionNumber><AccessionNumber>KF598704</AccessionNumber><AccessionNumber>KF598705</AccessionNumber><AccessionNumber>KF598706</AccessionNumber><AccessionNumber>KF598707</AccessionNumber><AccessionNumber>KF598708</AccessionNumber><AccessionNumber>KF598709</AccessionNumber><AccessionNumber>KF598710</AccessionNumber><AccessionNumber>KF598711</AccessionNumber><AccessionNumber>KF598712</AccessionNumber><AccessionNumber>KF598713</AccessionNumber><AccessionNumber>KF598714</AccessionNumber><AccessionNumber>KF598715</AccessionNumber><AccessionNumber>KF598716</AccessionNumber><AccessionNumber>KF598717</AccessionNumber><AccessionNumber>KF598718</AccessionNumber><AccessionNumber>KF598719</AccessionNumber><AccessionNumber>KF598720</AccessionNumber><AccessionNumber>KF598721</AccessionNumber><AccessionNumber>KF598722</AccessionNumber><AccessionNumber>KF598723</AccessionNumber><AccessionNumber>KF598724</AccessionNumber><AccessionNumber>KF598725</AccessionNumber><AccessionNumber>KF598726</AccessionNumber><AccessionNumber>KF598727</AccessionNumber><AccessionNumber>KF598728</AccessionNumber><AccessionNumber>KF598729</AccessionNumber><AccessionNumber>KF598730</AccessionNumber><AccessionNumber>KF598731</AccessionNumber><AccessionNumber>KF598732</AccessionNumber><AccessionNumber>KF598733</AccessionNumber><AccessionNumber>KF598734</AccessionNumber><AccessionNumber>KF598735</AccessionNumber><AccessionNumber>KF598736</AccessionNumber><AccessionNumber>KF598737</AccessionNumber><AccessionNumber>KF598738</AccessionNumber><AccessionNumber>KF598739</AccessionNumber><AccessionNumber>KF598740</AccessionNumber><AccessionNumber>KF598741</AccessionNumber><AccessionNumber>KF598742</AccessionNumber><AccessionNumber>KF598743</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>TPA-90193</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24446529</ArticleId><ArticleId IdType="pii">jiu048</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiu048</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name><name sortKey="Charest, Hugues" sort="Charest, Hugues" uniqKey="Charest H" first="Hugues" last="Charest">Hugues Charest</name><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name><name sortKey="Dickinson, James A" sort="Dickinson, James A" uniqKey="Dickinson J" first="James A" last="Dickinson">James A. Dickinson</name><name sortKey="Fonseca, Kevin" sort="Fonseca, Kevin" uniqKey="Fonseca K" first="Kevin" last="Fonseca">Kevin Fonseca</name><name sortKey="Gubbay, Jonathan B" sort="Gubbay, Jonathan B" uniqKey="Gubbay J" first="Jonathan B" last="Gubbay">Jonathan B. Gubbay</name><name sortKey="Janjua, Naveed Z" sort="Janjua, Naveed Z" uniqKey="Janjua N" first="Naveed Z" last="Janjua">Naveed Z. Janjua</name><name sortKey="Krajden, Mel" sort="Krajden, Mel" uniqKey="Krajden M" first="Mel" last="Krajden">Mel Krajden</name><name sortKey="Kwindt, Trijntje L" sort="Kwindt, Trijntje L" uniqKey="Kwindt T" first="Trijntje L" last="Kwindt">Trijntje L. Kwindt</name><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name><name sortKey="Sabaiduc, Suzana" sort="Sabaiduc, Suzana" uniqKey="Sabaiduc S" first="Suzana" last="Sabaiduc">Suzana Sabaiduc</name><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name><name sortKey="Winter, Anne Luise" sort="Winter, Anne Luise" uniqKey="Winter A" first="Anne-Luise" last="Winter">Anne-Luise Winter</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000274 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000274 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24446529
|texte= Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24446529" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |